Grifols SA (GRF), Europe’s largest maker of blood-plasma products, jumped the most in six months after Exane BNP Paribas said the global market for protein therapies derived from the material will expand in the next two years .
...
11 abril 2013
Yondelis® actúa Deplecionando los Macrófagos Asociados al Tumor. Este Mecanismo de acción es Particular a Yondelis® y no se observa con ninguna de los otros Agentes Antitumorales Estudiados.
En uno de los simposios de cierre del congreso AACR , la Dra Paola Allavena, colaboradora de PharmaMar en el Instituto Humanitas de Milán (Italia), fue invitada por el Comité Organizador del Congreso a presentar los datos que demuestran la actividad específica de Yondelis® sobre el microambiente tumoral. Es decir, además de inducir la muerte de las células tumorales, Yondelis® actúa deplecionando los macrófagos asociados al tumor. Estas células, que normalmente forman parte del sistema inmunológico, tienen en el tumor una actividad protumoral ya que liberan una serie de factores que estimulan la división de las células tumorales así como la formación de neovasos. Al inducir la muerte de éstas células, Yondelis® inhibe esta actividad protumoral y disminuye la secreción de los factores estimulantes del crecimiento tumoral. Este mecanismo de acción es particular a Yondelis® y no se observa con ninguna de los otros agentes antitumorales estudiados. Esto datos fueron recientemente publicados en la prestigiosa revista “Cancer Cell” .
Zeltia SA : PharmaMar presents five new trials with its marine-based drugs at the Annual Meeting of the American Association for Cancer Research (AACR) .
PM01183 ( 4 Presentaciones ) :
*.- SINERGIAS COMBINADO CON TOPOTECAN ( IRINOTECAN ) EN NSCLC, melanoma, hepatocarcinoma, colon, páncreas y glioma.
*.- SINERGIAS COMBINADO CON 5-FLUOROURACIL ( 5.FU ) EN GASTRO , PANCREAS Y COLON .
*.- SINERGIAS COMBINADO CON TAXANOS .
*.- Specifically targets RNA Pol II for degradation via the proteasome pathway in a TC-NER-dependent fashion .
*********************************
Aplidin ( 1 Presentacion ) :
*.- ( Apoptosis ) Triggers the activation of molecular components of the UPR as part of its pro-apoptotic program in tumor cells .
**********************************
Yondelis ( 5 Presentaciones No Pharma Mar ) :
*.- Bioimarcador STS .
*.- Mata Macrofagos .
*.- Sinergia en STS con Olaparib .
*.- Analogos del Yondelis se Muestra Mejor y más Potente en Sarcoma de Ewing que el propio ET743 .
*.- Resultados en Pacientes Retretrados .
***********************************************
Dr Paola Allavena, from Instituto Humanitas in Milan (Italy), was invited by the organising committee to speak in one of the closing symposia on the data showing the specific activity of Yondelis® in the tumour's microenvironment. In addition to inducing tumour cell death, Yondelis® depletes tumour-associated macrophages. Those cells, normally part of the immune system, exhibit protumoural activity by releasing a number of factors that stimulate tumour cell division and neovascularisation.
By inducing these cells' death, Yondelis® inhibits their protumoural activity and reduces the secretion of tumour growth stimulation factors. This action mechanism is specific to Yondelis® and has not been observed with any other antitumour agent to date. That data was recently published in "Cancer Cell" journal.
...
*.- SINERGIAS COMBINADO CON TOPOTECAN ( IRINOTECAN ) EN NSCLC, melanoma, hepatocarcinoma, colon, páncreas y glioma.
*.- SINERGIAS COMBINADO CON 5-FLUOROURACIL ( 5.FU ) EN GASTRO , PANCREAS Y COLON .
*.- SINERGIAS COMBINADO CON TAXANOS .
*.- Specifically targets RNA Pol II for degradation via the proteasome pathway in a TC-NER-dependent fashion .
*********************************
Aplidin ( 1 Presentacion ) :
*.- ( Apoptosis ) Triggers the activation of molecular components of the UPR as part of its pro-apoptotic program in tumor cells .
**********************************
Yondelis ( 5 Presentaciones No Pharma Mar ) :
*.- Bioimarcador STS .
*.- Mata Macrofagos .
*.- Sinergia en STS con Olaparib .
*.- Analogos del Yondelis se Muestra Mejor y más Potente en Sarcoma de Ewing que el propio ET743 .
*.- Resultados en Pacientes Retretrados .
***********************************************
Dr Paola Allavena, from Instituto Humanitas in Milan (Italy), was invited by the organising committee to speak in one of the closing symposia on the data showing the specific activity of Yondelis® in the tumour's microenvironment. In addition to inducing tumour cell death, Yondelis® depletes tumour-associated macrophages. Those cells, normally part of the immune system, exhibit protumoural activity by releasing a number of factors that stimulate tumour cell division and neovascularisation.
By inducing these cells' death, Yondelis® inhibits their protumoural activity and reduces the secretion of tumour growth stimulation factors. This action mechanism is specific to Yondelis® and has not been observed with any other antitumour agent to date. That data was recently published in "Cancer Cell" journal.
...
Suscribirse a:
Entradas (Atom)